FLT3 and acute myeloid leukemia: The most promising targets, CD33, CD123, CD135 (e.g. FLT3; FMS-like Tyrosine Kinase 3), and CLL-1 (C-type lectin-like molecule-1), are expressed in approximately 90-99%, 50-78%, 54-92%, and 78-92% of AML cases, respectively.123